Ensysce Biosciences, Inc. - Common Stock (ENSC)

SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~

Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~

Investor interest in low-priced growth stocks continues to build as companies across defense technology, artificial intelligence, biotechnology, digital media, and cross-border logistics announce significant business developments. Several stocks trading below the $1 level are attracting increased attention after releasing catalysts that could drive investor interest in the weeks ahead.

Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~

~ Patent Extends Jurisdiction and Protection Through 2042 ~

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~

Rapid Dose Therapeutics (CSE: DOSE; OTCQB: RDTCF ), a biotechnology and drug delivery innovation company, is accelerating clinical validation of its proprietary QuickStrip™ oral thin film delivery system through expanded cannabinoid research and a high-profile study supported by the National Football League (NFL) .

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~

~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch

~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~

~ New U.S. Patent Extends Protection Through 2042 ~

~ FDA Response Streamlines Path to Commercial Production of PF614~